Impact of Elexacaftor-tezacaftor-ivacaftor Triple Combination CFTR Therapy on Sinus Disease: Quantitative Sinus Computed Tomography, Patient Reported Outcomes and Cellular and Molecular Changes
Latest Information Update: 06 Mar 2023
At a glance
- Drugs Elexacaftor/ivacaftor/tezacaftor (Primary)
- Indications Cystic fibrosis
- Focus Pharmacodynamics
Most Recent Events
- 09 Mar 2021 Planned End Date changed from 1 Sep 2021 to 1 Jul 2022.
- 09 Mar 2021 Planned primary completion date changed from 1 Apr 2021 to 1 Jul 2021.
- 09 Mar 2021 Status changed from active, no longer recruiting to recruiting.